Standard
83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes. / Martin Jimenez, M.; Gnant, M.i.; Ejlertsen, B.; Mansi, J.l.; Ruiz-borrego, M.; Jakobsen, E.h.; Osborne, C.k.; Birhiray, R.; Zhang, B.; Wong, A.; Moy, B.; Holmes, F.a.
In:
Annals of Oncology, Vol. 31, No. S2, 01.05.2020, p. S43.
Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Harvard
Martin Jimenez, M, Gnant, MI
, Ejlertsen, B, Mansi, JL, Ruiz-borrego, M, Jakobsen, EH, Osborne, CK, Birhiray, R, Zhang, B, Wong, A, Moy, B & Holmes, FA 2020, '
83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes',
Annals of Oncology, vol. 31, no. S2, pp. S43.
https://doi.org/10.1016/j.annonc.2020.03.023APA
Martin Jimenez, M., Gnant, M. I.
, Ejlertsen, B., Mansi, J. L., Ruiz-borrego, M., Jakobsen, E. H., Osborne, C. K., Birhiray, R., Zhang, B., Wong, A., Moy, B., & Holmes, F. A. (2020).
83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes.
Annals of Oncology,
31(S2), S43.
https://doi.org/10.1016/j.annonc.2020.03.023Vancouver
Martin Jimenez M, Gnant MI
, Ejlertsen B, Mansi JL, Ruiz-borrego M, Jakobsen EH et al.
83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes.
Annals of Oncology. 2020 May 1;31(S2):S43.
https://doi.org/10.1016/j.annonc.2020.03.023Author
Martin Jimenez, M. ; Gnant, M.i. ; Ejlertsen, B. ; Mansi, J.l. ; Ruiz-borrego, M. ; Jakobsen, E.h. ; Osborne, C.k. ; Birhiray, R. ; Zhang, B. ; Wong, A. ; Moy, B. ; Holmes, F.a. / 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes. In: Annals of Oncology. 2020 ; Vol. 31, No. S2. pp. S43.
Bibtex
@article{6960f48872b0492ca08bf50ca1c64e4c,
title = "83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes",
author = "{Martin Jimenez}, M. and M.i. Gnant and B. Ejlertsen and J.l. Mansi and M. Ruiz-borrego and E.h. Jakobsen and C.k. Osborne and R. Birhiray and B. Zhang and A. Wong and B. Moy and F.a. Holmes",
year = "2020",
month = may,
day = "1",
doi = "10.1016/j.annonc.2020.03.023",
language = "English",
volume = "31",
pages = "S43",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "S2",
}
RIS
TY - ABST
T1 - 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes
AU - Martin Jimenez, M.
AU - Gnant, M.i.
AU - Ejlertsen, B.
AU - Mansi, J.l.
AU - Ruiz-borrego, M.
AU - Jakobsen, E.h.
AU - Osborne, C.k.
AU - Birhiray, R.
AU - Zhang, B.
AU - Wong, A.
AU - Moy, B.
AU - Holmes, F.a.
PY - 2020/5/1
Y1 - 2020/5/1
U2 - 10.1016/j.annonc.2020.03.023
DO - 10.1016/j.annonc.2020.03.023
M3 - Conference abstract in journal
VL - 31
SP - S43
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - S2
ER -
